share_log

Femasys | 8-K: Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Femasys | 8-K: Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Femasys | 8-K:Femasys公佈截至2024年9月30日的季度財務業績,並提供公司最新情況
美股SEC公告 ·  11/12 09:33

Moomoo AI 已提取核心訊息

On August 12, 2024, Femasys Inc., a biomedical company specializing in women's health, reported its financial results for the quarter ending September 30, 2024, and provided a corporate update. The company, listed on NASDAQ under the symbol FEMY, announced significant commercial progress, including partnerships in the U.S. and Europe, particularly with Boston IVF and the launch of FemaSeed in California and Florida. Femasys also reported strategic distribution partnerships in Spain for its CE-marked products, which are expected to generate over $1.3 million in the next year. The company received FDA 510(k) clearance for FemChec and Health Canada approval for FemVue MINI. A new U.S. patent was issued for the FemBloc device. Financially, Femasys saw a 127.1% increase in sales to $554,908 in Q3 2024 compared...Show More
On August 12, 2024, Femasys Inc., a biomedical company specializing in women's health, reported its financial results for the quarter ending September 30, 2024, and provided a corporate update. The company, listed on NASDAQ under the symbol FEMY, announced significant commercial progress, including partnerships in the U.S. and Europe, particularly with Boston IVF and the launch of FemaSeed in California and Florida. Femasys also reported strategic distribution partnerships in Spain for its CE-marked products, which are expected to generate over $1.3 million in the next year. The company received FDA 510(k) clearance for FemChec and Health Canada approval for FemVue MINI. A new U.S. patent was issued for the FemBloc device. Financially, Femasys saw a 127.1% increase in sales to $554,908 in Q3 2024 compared to the same period in 2023. R&D expenses rose by 11.1%, and the net loss for the quarter was $5.4 million, an increase from the previous year. The company's cash and cash equivalents stood at $7.6 million, with an accumulated deficit of $122.1 million. Femasys expects its current funds to sustain operations into July 2025. The full financial details are available in the company's Form 10-Q filed on November 12, 2024.
2024年8月12日,專注於婦女健康的生物醫藥公司Femasys Inc.報告了截至2024年9月30日的季度財務結果,並提供了公司更新。該公司在納斯達克上市,代碼爲FEMY,宣佈了重大商業進展,包括與美國和歐洲的合作伙伴關係,特別是與波士頓試管嬰兒中心以及在加利福尼亞和佛羅里達州推出FemaSeed。Femasys還報告了西班牙CE認證產品的戰略分銷合作伙伴關係,預計在未來一年將帶來超過130萬美元的收入。該公司獲得了FemChec的FDA 510(k)許可和FemVue MINI的加拿大衛生部批准。新的美國專利發放給了FemBloc設備。在財務方面,與2023年同期相比,Femasys在2...展開全部
2024年8月12日,專注於婦女健康的生物醫藥公司Femasys Inc.報告了截至2024年9月30日的季度財務結果,並提供了公司更新。該公司在納斯達克上市,代碼爲FEMY,宣佈了重大商業進展,包括與美國和歐洲的合作伙伴關係,特別是與波士頓試管嬰兒中心以及在加利福尼亞和佛羅里達州推出FemaSeed。Femasys還報告了西班牙CE認證產品的戰略分銷合作伙伴關係,預計在未來一年將帶來超過130萬美元的收入。該公司獲得了FemChec的FDA 510(k)許可和FemVue MINI的加拿大衛生部批准。新的美國專利發放給了FemBloc設備。在財務方面,與2023年同期相比,Femasys在2024年第三季度銷售額增長了127.1%,達到了554,908美元。研發費用增長了11.1%,本季度淨虧損爲540萬美元,較去年同期增加。該公司的現金及現金等價物爲760萬美元,累計虧損爲1,2210萬美元。Femasys預計目前的所有基金類型可支撐公司運營至2025年7月。公司完整的財務細節可在其於2024年11月12日提交的10-Q表格中找到。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息